Nuntius Therapeutics announces collaboration with Taiho Pharmaceutical to develop next-generation mRNA therapies
- Nuntius Therapeutics and Taiho Pharmaceutical have entered into a collaboration agreement to develop novel mRNA cancer immunotherapies.
- Taiho will utilize Nuntius' cell-specific peptide dendrimer- and lipid-based nanocarriers for the development.
- The collaboration follows a successful feasibility study evaluating Nuntius' delivery capabilities.
- Financial terms of the agreement were not disclosed.
Read more
Children's Hospital of Philadelphia researchers reveal new hope for chemotherapy-resistant neuroblastoma patients
- Researchers at CHOP identified malignant cells responsible for relapse in high-risk neuroblastoma.
- The study utilized advanced single nucleus RNA sequencing and bulk whole genome sequencing techniques.
- Findings suggest that 'non-cycling' cells evade chemotherapy by becoming dormant, leading to relapse.
- Several immunotherapeutic strategies to eliminate these persister cells are already being tested.
Read more
The American Journal of Gastroenterology publishes Esopredict performance results from pivotal clinical validation study
- Esopredict is a DNA methylation test predicting progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett's esophagus patients.
- The study included 240 patients from six U.S. clinical sites, with samples processed at Previse's CLIA laboratory.
- High-risk patients identified by Esopredict had a 22% risk of progression within five years, while low-risk patients had only a 1.9% risk.
- Esopredict provides a personalized risk score and probability of progression, aiding early intervention and treatment.
Read more
